Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11782833 | 0.86 | GABRA1 (0.46) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL21132607 | 0.84 | TSHR (0.37) | LMNATSHRHPGDKCNK3KCNK9 | |
| SCHEMBL1535968 | 0.84 | TSHR (0.53) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL16952312 | 0.83 | LMNA (0.48) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL1635308 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL29567244 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL24692389 | 0.82 | IRAK4 (0.44) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL1536722 | 0.82 | GABRA1 (0.43) | GABRA1GABRG2GABRB3LMNAGABRB2 | |
| SCHEMBL20365188 | 0.82 | ACE2 (0.39) | LMNASLC6A2HTR2BSMN1; SMN2 | |
| Hydrogen Peroxide SCHEMBL1652481 | 0.81 | GABRA1 (0.48) | GABRA1GABRG2GABRB3LMNAGABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-12-03 | — | — | US | disclosed |
| WO-2009140275-A1 | ANALOGS OF PROPOFOL, PREPARATION THEREOF AND USE AS ANESTHETICS | PHARMACOFORE, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-08 | — | — | US | disclosed |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-16 | — | — | US | disclosed |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066150-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | GABRA1 1032/4885GABRG2 836/4885GABRB3 350/4885 |
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, ODC1, LEF1 | GABRA1 3315/4885GABRG2 4172/4885GABRB3 3804/4885 |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | GABRA1 3200/4885GABRG2 4064/4885GABRB3 3757/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | GABRA1 1087/4885GABRG2 1920/4885GABRB3 1892/4885 |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | ALDH1A2, ODC1, NDUFS2 | GABRA1 3608/4885GABRG2 4378/4885GABRB3 3976/4885 |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | ALPI, IK, ALDH1A2 | GABRA1 4353/4885GABRG2 4673/4885GABRB3 4685/4885 |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | GABRA1 3597/4885GABRG2 4294/4885GABRB3 4119/4885 |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | IK, TYR, EYA2 | GABRA1 4267/4885GABRG2 4431/4885GABRB3 4379/4885 |
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ODC1, AOX1, OR10J3 | GABRA1 3095/4885GABRG2 3868/4885GABRB3 3366/4885 |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | GABRA1 3507/4885GABRG2 4301/4885GABRB3 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.